Figure 2.
Progression-free survival. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the treatment group and 8.6 months in the control group.
Progression-free survival. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the treatment group and 8.6 months in the control group.